BLFS · As filed with the SEC

Biolife Solutions income statement, by quarter

The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Unaudited Condensed Consolidated Statements of Operations · USD thousands, except per-share amounts

USD thousands, except per-share amounts	Q2 2026 3 months ended Jun 30, 2026	Q1 2026 3 months ended Mar 31, 2026	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q4 2024^† 3 months ended Dec 31, 2024
Revenue	28,466	27,500	18,785^†	28,067	25,421	22,715^†
Product revenue	—	—	—	26,250	23,709	21,245^†
Service revenue	—	—	—	26	36	41^†
Rental revenue	—	—	—	1,791	1,676	1,429^†
Cost of revenue	10,179	10,004	—	—	8,203^†	—
Gross profit	18,287	17,496	—	—	15,235^†	—
Operating expenses:
Product revenue	—	—	—	9,288	8,035	7,207^†
Service revenue	—	—	—	7	9	9^†
Rental revenue	—	—	—	851	944	1,267^†
General and administrative	10,694	12,208	10,550^†	12,074	11,396	11,500^†
Sales and marketing	2,782	2,526	1,993^†	2,528	2,732	2,244^†
Research and development	2,958	2,650	(67)^†	2,709	2,719	1,915^†
IPR&D expense	0	—	0^†	0	15,521	0^†
Intangible asset amortization	157	85	(1,846)^†	699	708	683^†
Total operating expenses	16,591	17,469	(16,658)^†	28,156	42,064	24,825^†
Operating income (loss)	1,696	27	1,347^†	(89)	(16,643)	(2,110)^†
Other income:
Interest income, net	994	1,041	833^†	508	684	(24)^†
Other income	63	180	1,182^†	284	247	1^†
Change in fair value of investments	—	—	0^†	0	0	0^†
Total other income, net	1,057	1,221	2,015^†	792	931	(23)^†
Income (loss) before income tax (benefit) expense	2,753	1,248	3,362^†	703	(15,712)	(2,133)^†
Income tax (benefit) expense	(42,351)	62	271^†	(82)	(126)	(24)^†
Net income (loss) from continuing operations	45,104	1,186	3,535^†	621	(15,838)	(2,157)^†
Discontinued operations:
Loss from discontinued operations before income tax benefit	0	0	7,535^†	0	0	14,582^†
Income tax benefit	0	0	0^†	0	0	34^†
Loss from discontinued operations	0	0	7,535^†	0	0	14,616^†
Net income (loss)	45,104	1,186	11,070^†	621	(15,838)	12,459^†
Basic	—	—	—	—	(15,838)	—
Diluted	—	—	—	—	(15,838)	—
Basic	—	—	—	—	0	—
Diluted	—	—	—	—	0	—
Net income (loss) per share - Basic:
Continuing operations (in dollars per share)	0.92	0.02	—	0.01	(0.33)	—
Discontinuing operations (in dollars per share)	—	—	—	—	0.00	—
Discontinued operations (in dollars per share)	0.00	0.00	—	0.00	—	—
Net income (loss) per share (in dollars per share)	0.92	0.02	—	0.01	(0.33)	—
Net income (loss) per share - Diluted:
Continuing operations (in dollars per share)	0.91	0.02	—	0.01	(0.33)	—
Discontinuing operations (in dollars per share)	—	—	—	—	0.00	—
Basic	—	—	—	—	(15,838)	—
Diluted	—	—	—	—	(15,838)	—
Discontinued operations (in dollars per share)	0.00	0.00	—	0.00	—	—
Net income per share (in dollars per share)	0.91	0.02	—	0.01	(0.33)	—
Weighted average shares used to compute income (loss) per share:
Basic (in shares)	48,866,822	48,458,536	—	47,925,038	47,798,146	—
Diluted (in shares)	49,294,679	49,248,075	—	48,723,535	47,798,146	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.